SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates3/29/2010 11:53:11 AM
   of 1022
 
GHENT, Belgium, 26 March 2010 - Ablynx [Euronext Brussels: ABLX] announced today that it
has advanced ALX-0171, a new Nanobody®-based therapeutic programme, into pre-clinical
development for the treatment of respiratory synctial virus (RSV) infections. ALX-0171 is a
Nanobody product which binds to RSV and neutralizes the virus. The Nanobody will be administered
via the lungs and based on the in vivo data it has the potential to be effective both in the prevention of
infection as well as in treatment once infection has occurred.

This is Ablynx’s first Nanobody pre-clinical development candidate to be delivered through a route
other than injection. Like many Nanobodies, ALX-0171 is very stable with a low propensity to
aggregate making it suitable for inhalation. It can also be manufactured at relatively low cost in
microbial systems.

“Ablynx’s anti-RSV Nanobody potentially has a clearly differentiated product profile compared with
other options currently available for RSV. We expect to conveniently deliver ALX-0171 via the lungs
directly to the site of potential disease to provide prophylactic protection, as well as therapeutic
treatment which we don’t believe can be offered for this infectious agent by any other marketed drugs
today. We also believe ALX-0171 will have a significantly lower cost of goods compared to other
biologics currently used in this indication. We are very pleased to illustrate the power of our
Nanobody product engine with this announcement of our second pre-clinical candidate nomination in
2010. Earlier this year we nominated ALX-0651, an anti-CXCR4 Nanobody for stem cell
mobilization, for preclinical development”, commented Dr. Edwin Moses, Chief Executive Officer
and Chairman of Ablynx.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News